A large study published in Digestive Surgery showed that more than 90% of patients develop adhesions following open abdominal surgery and 55% to 100% of women develop adhesions following pelvic surgery. (Liakakos et al., 2001) Small-bowel obstruction, infertility, chronic abdominal and pelvic pain, and difficult reoperative surgery are the most common consequences of peritoneal adhesions. Despite elaborate efforts to develop effective strategies to reduce or prevent adhesions, their formation remains a frequent occurrence after abdominal surgery. Thus, many patients become trapped in a cycle of surgery-adhesions-surgery – with no end in sight.
The phase III ALCYONE study is a randomized, open-label, multicenter study that includes 706 newly diagnosed patients with multiple myeloma who are ineligible for autologous stem cell transplantation. Patients were randomized to receive 9 cycles of either daratumumab combined with VMP and prednisone or VMP alone. In the daratumumab treatment arm, patients received 16 mg/kg of daratumumab once weekly for 6 weeks (cycle 1), followed by once every 3 weeks (cycles 2–9). Following the 9 cycles, patients in the daratumumab treatment arm continued to receive 16 mg/kg of daratumumab once every 4 weeks until disease progression. The primary endpoint of the study is progression-free survival.